Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Does red blood cell distribution width predict prognosis in metastatic renal cell carcinoma patients using first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy?
Korkmaz M, Eryılmaz MK, Koçak MZ, Er MM, Hendem E, Demirkıran A, Araz M, Karaağaç M, Artaç M. Korkmaz M, et al. Among authors: kocak mz. J Cancer Res Ther. 2023 Apr;19(Supplement):S0. doi: 10.4103/jcrt.jcrt_898_22. J Cancer Res Ther. 2023. PMID: 37147975 Free article.
The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study.
Uğraklı M, Koçak MZ, Dinç G, Genç TB, Çağlayan M, Uğraklı S, Hendem E, Er MM, Çağlayan D, Eryılmaz MK, Araz M, Geredeli Ç, Tatlı AM, Eren OÖ, Artaç M. Uğraklı M, et al. Among authors: kocak mz. J Cancer Res Clin Oncol. 2023 Sep;149(11):9183-9189. doi: 10.1007/s00432-023-04844-6. Epub 2023 May 15. J Cancer Res Clin Oncol. 2023. PMID: 37184681
PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study.
Avcı O, İriağaç Y, Çavdar E, Karaboyun K, Araz M, Şakalar T, Değerli E, Özdemir Ö, İnal A, Ocak B, Ürün M, Sakin A, Yıldız Tacar S, Koçak MZ, Demir H, Özer Ö, Tanrıkulu Şimşek E, Ersoy M, Karakaş Y, Arıkan R, Eşbah O, Ön S, Şenocak Taşçı E, Molinas Mandel N, Türker S, Kaçan T, Yıldırım HÇ, Alan Ö, Akbaş S, İpek Deniz G, Aydın İsak Ö, Taşkaynatan H, Şeber ES. Avcı O, et al. Among authors: kocak mz. J Geriatr Oncol. 2023 Nov;14(8):101604. doi: 10.1016/j.jgo.2023.101604. Epub 2023 Sep 6. J Geriatr Oncol. 2023. PMID: 37683369
The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line.
Korkmaz M, Eryılmaz MK, Koçak MZ, Er MM, Hendem E, Demirkıran A, Araz M, Artaç M. Korkmaz M, et al. Among authors: kocak mz. Eur J Clin Pharmacol. 2024 Jun;80(6):941-947. doi: 10.1007/s00228-024-03668-8. Epub 2024 Mar 13. Eur J Clin Pharmacol. 2024. PMID: 38478093
Is the Prognostic Nutritional Index a Prognostic Marker for the Survival of Patients with Lymph-Node Positive Stage II-III Gastric Cancer Who Receive Adjuvant Chemotherapy?
Korkmaz M, Eryılmaz MK, Er MM, Koçak MZ, Demirkıran A, Karaağaç M, Araz M, Artaç M, Koçak ZM. Korkmaz M, et al. Among authors: kocak mz. J Gastrointest Cancer. 2023 Sep;54(3):962-969. doi: 10.1007/s12029-023-00972-x. Epub 2023 Sep 22. J Gastrointest Cancer. 2023. PMID: 37737437
40 results